Prevention and Early Treatment of Opportunistic Viral Infections in Patients With Leukemia and Allogeneic Stem Cell Transplantation Recipients

Authors: Michael Angarone DO a and Michael G. Ison MD, MS a , a
View More View Less
  • a From the Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

A leading complication of leukemia therapy and stem cell transplantation is opportunistic viral infections. Infections caused by cytomegalovirus, herpes simplex, varicella-zoster, Epstein-Barr, and the community respiratory viruses are associated with significant morbidity and mortality in this highly immunosuppressed population. Fortunately, a growing armamentarium is allowing more effective prophylaxis of these pathogens. This article reviews the epidemiology and prophylactic strategies available for these common opportunistic viral pathogens.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Michael G. Ison, MD, MS, Northwestern University Feinberg School of Medicine, Division of Infectious Diseases, 676 North St. Clair Street, Suite 200, Chicago, Illinois 60611. E-mail: mgison@northwestern.edu
  • 1.

    Sandherr M, Einsele H, Hebart H. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:10511059.

    • Search Google Scholar
    • Export Citation
  • 2.

    Griffiiths P, Emery V. Cytomegalovirus. Washington, D.C.; ASM Press; 2002.

  • 3.

    Ng AP, Worth L, Chen L. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica 2005;90:16721679.

    • Search Google Scholar
    • Export Citation
  • 4.

    Thursky KA, Worth LJ, Seymour JF. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol 2006;132:312.

    • Search Google Scholar
    • Export Citation
  • 5.

    Laurenti L, Piccioni P, Cattani P. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:12481252.

    • Search Google Scholar
    • Export Citation
  • 6.

    Keating M, Coutre S, Rai K. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220227.

    • Search Google Scholar
    • Export Citation
  • 7.

    Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49:1125. Erratum in: MMWR Recomm Rep 2004;53:396.

    • Search Google Scholar
    • Export Citation
  • 8.

    Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1999;1:165178.

    • Search Google Scholar
    • Export Citation
  • 9.

    Boeckh M, Ljungman P. Cytomegalovirus infections after hemopoietic stem cell transplantation. Philadelphia; Lippincott Williams & Wilkins; 2003.

    • Search Google Scholar
    • Export Citation
  • 10.

    Meyers JD, Reed EC, Shepp DH. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:7075.

    • Search Google Scholar
    • Export Citation
  • 11.

    Miller W, Flynn P, McCullough J. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986;67:11621167.

    • Search Google Scholar
    • Export Citation
  • 12.

    Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 2005;26:691705, viii.

  • 13.

    Ljungman P, Reusser P, de la Camara R. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004;33:10751081.

    • Search Google Scholar
    • Export Citation
  • 14.

    Bowden RA, Slichter SJ, Sayers M. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:35983603.

    • Search Google Scholar
    • Export Citation
  • 15.

    Bowden RA, Slichter SJ, Sayers MH. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246250.

    • Search Google Scholar
    • Export Citation
  • 16.

    Miller WJ, McCullough J, Balfour HH Jr. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991;7:227234.

    • Search Google Scholar
    • Export Citation
  • 17.

    Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002;35:9991004.

  • 18.

    Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003;16:647657.

    • Search Google Scholar
    • Export Citation
  • 19.

    Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006;71:154163.

  • 20.

    De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115133.

  • 21.

    Wang LH, Peck RW, Yin Y. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003;47:13341342.

    • Search Google Scholar
    • Export Citation
  • 22.

    Tyms A, Scamans EM, Naim M. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections. J Antimicrob Chemother 1981;8:6572.

    • Search Google Scholar
    • Export Citation
  • 23.

    Goodrich JM, Bowden RA, Fisher L. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173178.

    • Search Google Scholar
    • Export Citation
  • 24.

    Winston DJ, Ho WG, Bartoni K. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993;118:179184.

    • Search Google Scholar
    • Export Citation
  • 25.

    Boeckh M, Gooley TA, Myerson D. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996;88:40634071.

    • Search Google Scholar
    • Export Citation
  • 26.

    Boeckh M, Zaia JA, Jung D. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 1998;4:1319.

    • Search Google Scholar
    • Export Citation
  • 27.

    Szer J, Durrant S, Schwarer AP. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Intern Med J 2004;34:98101.

    • Search Google Scholar
    • Export Citation
  • 28.

    Talarico CL, Burnette TC, Miller WH. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999;43:19411946.

    • Search Google Scholar
    • Export Citation
  • 29.

    Mori T, Aisa Y, Shimizu T. Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor. Int J Hematol 2006;83:266270.

    • Search Google Scholar
    • Export Citation
  • 30.

    Prentice HG, Gluckman E, Powles RL. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994;343:749753.

    • Search Google Scholar
    • Export Citation
  • 31.

    Burns LJ, Miller W, Kandaswamy C. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 2002;30:945951.

    • Search Google Scholar
    • Export Citation
  • 32.

    Boeckh M, Gooley TA, Bowden RA. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998;178:11531157.

    • Search Google Scholar
    • Export Citation
  • 33.

    Winston DJ, Yeager AM, Chandrasekar PH. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003;36:749758.

    • Search Google Scholar
    • Export Citation
  • 34.

    Ma JD, Nafziger AN, Villano SA. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyl-transferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 2006;50:11301135.

    • Search Google Scholar
    • Export Citation
  • 35.

    Winston D, Van Burik J, Pullarkat. Prophylaxis against cytomegalovirus infections with oral Maribavir in allogenic stem cell transplant recipient: results of a randomized, double-blind, placebo-controlled trial. Presented at the 48th American Society of Hematology Annual Meeting; Orlando, Florida; December 9–12, 2006.

    • Search Google Scholar
    • Export Citation
  • 36.

    Ippoliti C, Morgan A, Warkentin D. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997;20:491495.

    • Search Google Scholar
    • Export Citation
  • 37.

    Ljungman P, Deliliers GL, Platzbecker U. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388392.

    • Search Google Scholar
    • Export Citation
  • 38.

    Visani G, Mele A, Guiducci B. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. Leuk Lymphoma 2006;47:25422546.

    • Search Google Scholar
    • Export Citation
  • 39.

    Bass EB, Powe NR, Goodman SN. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993;12:273282.

    • Search Google Scholar
    • Export Citation
  • 40.

    Bowden RA, Fisher LD, Rogers K. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991;164:483487.

    • Search Google Scholar
    • Export Citation
  • 41.

    Bowden RA, Sayers M, Flournoy N. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:10061010.

    • Search Google Scholar
    • Export Citation
  • 42.

    Ruutu T, Ljungman P, Brinch L. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant 1997;19:233236.

    • Search Google Scholar
    • Export Citation
  • 43.

    Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1994;13:163167.

    • Search Google Scholar
    • Export Citation
  • 44.

    Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant Proc 1996;28(6 Suppl 2):1724.

    • Search Google Scholar
    • Export Citation
  • 45.

    Howden BP, Michaelides A, Spelman DW. Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis. Bone Marrow Transplant 2003;32:795800.

    • Search Google Scholar
    • Export Citation
  • 46.

    Nicholson VA, Whimbey E, Champlin R. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Bone Marrow Transplant 1997;19:3741.

    • Search Google Scholar
    • Export Citation
  • 47.

    van der Bij W, Schirm J, Torensma R. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 1988;26:25312535.

    • Search Google Scholar
    • Export Citation
  • 48.

    Machida U, Kami M, Fukui T. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol 2000;38:25362542.

    • Search Google Scholar
    • Export Citation
  • 49.

    Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002;40:746752.

    • Search Google Scholar
    • Export Citation
  • 50.

    Emery VC, Sabin CA, Cope AV. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000;355:20322036.

    • Search Google Scholar
    • Export Citation
  • 51.

    Ljungman P, Aschan J, Lewensohn-Fuchs I. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998;66:13301334.

    • Search Google Scholar
    • Export Citation
  • 52.

    Salzberger B, Bowden RA, Hackman RC. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997;90:25022508.

    • Search Google Scholar
    • Export Citation
  • 53.

    Ayala E, Greene J, Sandin R. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851856.

    • Search Google Scholar
    • Export Citation
  • 54.

    Busca A, de Fabritiis P, Ghisetti V. Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 2007;9:102107.

    • Search Google Scholar
    • Export Citation
  • 55.

    van der Heiden PL, Kalpoe JS, Barge RM. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006;37:693698.

    • Search Google Scholar
    • Export Citation
  • 56.

    Reusser P, Einsele H, Lee J. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:11591164.

    • Search Google Scholar
    • Export Citation
  • 57.

    Management of herpes virus infections following transplantation. J Antimicrob Chemother 2000;45:729748.

  • 58.

    Gnann J. Herpes Simplex and Varicella Zoster Virus Infection After Hemopoietic Stem Cell or Solid Organ Transplantation. 2nd ed. Philadelphia; Lippincott Williams & Wilkins; 2003.

    • Search Google Scholar
    • Export Citation
  • 59.

    Schubert MM, Peterson DE, Flournoy N. Oral and pharyngeal herpes simplex virus infection after allogeneic bone marrow transplantation: analysis of factors associated with infection. Oral Surg Oral Med Oral Pathol 1990;70:286293.

    • Search Google Scholar
    • Export Citation
  • 60.

    Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 1997;15:22692274.

    • Search Google Scholar
    • Export Citation
  • 61.

    Morrison VA, Rai KR, Peterson BL. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001;19:36113621.

    • Search Google Scholar
    • Export Citation
  • 62.

    Lundgren G, Wilczek H, Lonnqvist B. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl 1985;47:137144.

  • 63.

    Morfin F, Bilger K, Boucher A. HSV excretion after bone marrow transplantation: a 4-year survey. J Clin Virol 2004;30:341345.

  • 64.

    Saral R, Burns WH, Laskin OL. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:6367.

  • 65.

    Engelhard D, Morag A, Or R. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts. Isr J Med Sci 1988;24:145150.

    • Search Google Scholar
    • Export Citation
  • 66.

    Gluckman E, Lotsberg J, Devergie A. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 1983;2:706708.

    • Search Google Scholar
    • Export Citation
  • 67.

    Dignani MC, Mykietiuk A, Michelet M. Valacyclovir prophylaxis for the prevention of herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant 2002;29:263267.

    • Search Google Scholar
    • Export Citation
  • 68.

    Eisen D, Essell J, Broun ER. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 2003;31:5155.

    • Search Google Scholar
    • Export Citation
  • 69.

    Erard V, Wald A, Corey L. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007;196:266270.

    • Search Google Scholar
    • Export Citation
  • 70.

    Hann IM, Prentice HG, Blacklock HA. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983;287:384388.

    • Search Google Scholar
    • Export Citation
  • 71.

    Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 1995;310:11691172.

    • Search Google Scholar
    • Export Citation
  • 72.

    Warkentin DI, Epstein JB, Campbell LM. Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. Ann Pharmacother 2002;36:15251531.

    • Search Google Scholar
    • Export Citation
  • 73.

    Gershon A, Silverstein A. Varicella-Zoster Virus. 2nd ed. Washington, D.C.; ASM Press; 2002.

  • 74.

    Wade JC. Viral infections in patients with hematological malignancies. Hematology Am Soc Hematol Educ Program 2006:368374.

  • 75.

    Kim DH, Messner H, Minden M. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2007; Epub ahead of print.

    • Search Google Scholar
    • Export Citation
  • 76.

    Koc Y, Miller KB, Schenkein DP. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:4449.

    • Search Google Scholar
    • Export Citation
  • 77.

    Ljungman P, Lonnqvist B, Gahrton G. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986;153:840847.

    • Search Google Scholar
    • Export Citation
  • 78.

    Steer CB, Szer J, Sasadeusz J. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000;25:657664.

    • Search Google Scholar
    • Export Citation
  • 79.

    Erard V, Guthrie KA, Varley C. One-year acyclovir prophylaxis for preventing varicella-zoster virus (VZV) disease following hematopoietic cell transplantation: no evidence of rebound VZV disease after drug discontinuation. Blood 2007;110:30713077.

    • Search Google Scholar
    • Export Citation
  • 80.

    Boeckh M, Kim HW, Flowers ME. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 2006;107:18001805.

    • Search Google Scholar
    • Export Citation
  • 81.

    Zaia JA, Levin MJ, Preblud SR. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983;147:737743.

    • Search Google Scholar
    • Export Citation
  • 82.

    UpToDate. Albrecht MA. Treatment and prevention of chickenpox. Available at: www.UpToDate.com. Accessed December 31, 2007.

  • 83.

    Asano Y, Yoshikawa T, Suga S. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993;92:219222.

  • 84.

    Weinstock DM, Boeckh M, Boulad F. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol 2004;25:603608.

    • Search Google Scholar
    • Export Citation
  • 85.

    Sauerbrei A, Prager J, Hengst U. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997;20:381383.

    • Search Google Scholar
    • Export Citation
  • 86.

    Hata A, Asanuma H, Rinki M. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:2634.

    • Search Google Scholar
    • Export Citation
  • 87.

    Redman RL, Nader S, Zerboni L. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997;176:578585.

    • Search Google Scholar
    • Export Citation
  • 88.

    Preiksaitis J, Cockfiels S. Epstein-Barr Virus Infection and Lymphoproliferative Disease after Hemopoietic Stem Cell or Solid Organ Transplantation. 2nd ed. Philadelphia; Lippincott Williams & Wilkins; 2003.

    • Search Google Scholar
    • Export Citation
  • 89.

    Shapiro RS, McClain K, Frizzera G. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:12341243.

    • Search Google Scholar
    • Export Citation
  • 90.

    Weinstock DM, Ambrossi GG, Brennan C. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539546.

    • Search Google Scholar
    • Export Citation
  • 91.

    Zutter MM, Martin PJ, Sale GE. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72:520529.

  • 92.

    Greenfield HM, Gharib MI, Turner AJ. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Pediatr Blood Cancer 2006;47:200205.

    • Search Google Scholar
    • Export Citation
  • 93.

    van Esser JW, Niesters HG, van der Holt B. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:43644369.

    • Search Google Scholar
    • Export Citation
  • 94.

    Comoli P, Basso S, Zecca M. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007;7:16481655.

    • Search Google Scholar
    • Export Citation
  • 95.

    Gruhn B, Meerbach A, Hafer R. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;31:10231025.

    • Search Google Scholar
    • Export Citation
  • 96.

    Rooney CM, Smith CA, Ng CY. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:913.

    • Search Google Scholar
    • Export Citation
  • 97.

    Gustafsson A, Levitsky V, Zou JZ. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95:807814.

    • Search Google Scholar
    • Export Citation
  • 98.

    Papadopoulos EB, Ladanyi M, Emanuel D. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:11851191.

    • Search Google Scholar
    • Export Citation
  • 99.

    Ison MG. Respiratory viral infections in transplant recipients. Curr Opin Organ Transplant 2005;10:312319.

  • 100.

    Nichols WG, Erdman DD, Han A. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004;10:5864.

    • Search Google Scholar
    • Export Citation
  • 101.

    Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001;7(Suppl):11S5S.

    • Search Google Scholar
    • Export Citation
  • 102.

    Smith NM, Bresee JS, Shay DK. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:142.

    • Search Google Scholar
    • Export Citation
  • 103.

    Ison MG. Respiratory viral infections in transplant recipients. Antiviral Therapy 2007;12:627638.

  • 104.

    Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002;15:355367.

    • Search Google Scholar
    • Export Citation
  • 105.

    Kobashigawa JA, Warner-Stevenson L, Johnson BL. Influenza vaccine does not cause rejection after cardiac transplantation. Transplant Proc 1993;25:27382739.

    • Search Google Scholar
    • Export Citation
  • 106.

    Bright RA, Shay DK, Shu B. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 2006;295:891894.

    • Search Google Scholar
    • Export Citation
  • 107.

    Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:13631373.

  • 108.

    Chien JW, Martin PJ, Gooley TA. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003;168:208214.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 185 85 4
PDF Downloads 65 39 3
EPUB Downloads 0 0 0